Arch Therapeutics

 Fact Sheet

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Find a broker to begin trading ARTH now

Investment HighlightsValue Proposition
Company Name Arch Therapeutics
Market/Symbol OTCQB: ARTH
Recent Price
Market Cap $78.51M
Avg. Daily Vol. (3m) 435,960
Price/Book N/A
Price/Cash Flow N/A
As of Jan. 23, 2018
*Source: QuoteMedia

Begin trading ARTH

 Find Broker



Recent Company Videos

Arch Therapeutics: Innovative Technology to Stop Surgical Bleeding

May. 21, 2015

Dave Gentry, host of "The RedChip Money Report: Small Stocks Big Money,” interviews Dr. Terrence Norchi, President & CEO of Arch Therapeutics (OTCQB: ...

Investment Highlights

  • European clinical trial expected to commence in 1H15

Hemostat and sealant worldwide market revenues are projected to grow from $4.5 billion in 2013 to $6.7 billion in 2017 (10% CAGR)

  • Current relevant hemostat and sealant solutions sell from $20 to $500; AC5 is expected to deliver value equal to or greater than currently available solutions

Potential for high, biopharma type margins with relatively low, medical device capital requirements and a shorter medical device development timeline

  • Biomaterials present safety, efficacy, and ease of use challenges
  • Time to hemostasis for most competing products is measured in minutes

  • Time to hemostasis with AC5 is faster than that reported by competing products
  • AC5 works well in presence of anticoagulants, which are taken by over 7 million Americans over age 65. AC5 stopped bleeding in animals treated with therapeutic doses of anticoagulants (blood thinners) as fast as it stopped bleeding in animals not treated
  • In vitro safety tests on 282 known human receptor and enzyme targets, AC5 showed no interaction, supporting its safety profile and straightforward mechanism of action

  • $13 billion in annual wound management revenue

Value Proposition

ARTH is developing a potential blockbuster technology to treat the $5 billion and growing hemostat and sealant market. This is a market with many flawed solutions, thus generating the need for a safe, effective, and easy to use solution. Surgeons and potential industry partners are looking for better products with novel mechanisms of action.
Preclinical studies to date support a strong efficacy and safety profile, as well as other differentiating characteristics of AC5 versus the competition. The Company anticipates high gross margins and a short time to commercialization, with the potential to generate a strong ROI for investors.

Arch Therapeutics Latest News

Ask the CEO

ARTH Research

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive ARTH Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market